Bordbar 2008.

Methods	Allocation: randomised, no further details Blindness: no further details. Duration: six weeks Setting: inpatients, Iran Design: parallel, three groups
Participants	Diagnosis: schizophrenia (DSM‐IV) + PANSS negative >14. N = 80 (10 excluded). Sex: 45M, 45 F. Age: average ˜ 48 yrs
Interventions	1. Selegiline: 5 mg / day. N = 25 2. Selegiline: 10 mg/day. N = 25. 3. Placebo. N = 30. Stable neuroleptic medication:
Outcomes	Leaving the study early. Mental state: PANSS (negative and positive endpoint scores). Unable to use: safety (not reported).
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Table of random numbers".
Allocation concealment (selection bias)	Unclear risk	No further information.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"Identical placebo".
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No further information.
Incomplete outcome data (attrition bias) All outcomes	High risk	Completer analysis, 10 patients excluded.
Selective reporting (reporting bias)	Low risk	Main outcomes reported.
Other bias	Low risk	None obvious.